Related Experiment Video
Updated: May 22, 2026

Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development
Published on: October 30, 2013
Association between pioglitazone and urothelial bladder cancer
Yanina Barbalat1, Viktor Y Dombrovskiy, Robert E Weiss
1UMDNJ-Robert Wood Johnson Medical School, New Brunswick, NJ 08901, USA. yanabarbalat@gmail.com
Abstract:
The U.S. Food and Drug Administration and the European Medicines Agency have recently informed the public of a potential impact of pioglitazone (Actos) use on bladder cancer incidence. These recommendations are based on 2 recent large published cohort studies indicating a possible association between pioglitazone use and bladder cancer development. Currently, there is no urology literature on this subject. We present the current literature reporting the association between pioglitazone and bladder cancer.
Related Concept Videos
Oral Hypoglycemic Agents: Biguanides and Glitazones
Dipeptidyl Peptidase 4 Inhibitors
Urinary Tract Calculi II: Pathophysiology and Clinical Manifestations
Peptic Ulcer Disease I: Introduction
An acute ulcer, marked by superficial erosion and minimal inflammation, swiftly resolves upon identifying and addressing the underlying cause. In contrast, a chronic ulcer persists, potentially eroding through the muscular wall and forming fibrous tissue.
Peptic ulcers can also be...
Nursing Assessment of the Genitourinary System I: Health History
Urinary Tract Infection II: Pathophysiology

